Inactive Instrument
ReNeuron Group plc Stock
Stocks
RENE
GB00BF5G6K95
Biotechnology & Medical Research
OTC Markets Traded
| 24-02-06 | RENEURON ISSUES ADMINISTRATION WARNING | AQ |
| 23-11-27 | Edison issues update on ReNeuron Group (RENE): H124 results reaffirm focus on CustomEX™ | EQ |
| 23-11-16 | ReNeuron : Interim Statement 2023 | PU |
| 23-11-07 | ReNeuron : Presentation | PU |
| 23-07-24 | ReNeuron : 24 July 2023 – Notice of Annual General Meeting | PU |
| 1 day | -2.17% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 2025-03-23 |
| Director | Title | Age | Since |
|---|---|---|---|
Iain Ross
CHM | Chairman | 72 | 2021-06-30 |
| Director/Board Member | 63 | 2021-07-13 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 7/12/23 | Buy | Chief Financial Officer | 52,332 | 0.0915% | ||
| 6/16/23 | Buy | Director | 150,000 | 0.2624% | ||
| 6/16/23 | Buy | Chairman | 150,000 | 0.2624% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.17% | -11.18% | - | - | 2.58M | |
| +0.22% | +0.07% | -1.90% | +26.89% | 45.81B | |
| -3.11% | -4.18% | +345.17% | +543.36% | 43.91B | |
| +0.63% | +5.68% | +45.38% | +29.73% | 44.39B | |
| -0.09% | -1.10% | +6.09% | +66.16% | 39.4B | |
| -0.17% | -3.22% | +9.45% | +38.69% | 31.26B | |
| +2.73% | -5.49% | - | - | 15.75B | |
| -0.07% | +5.72% | +26.30% | +126.97% | 17.32B | |
| +1.66% | +5.30% | +19.25% | +35.77% | 14.73B | |
| +2.04% | +0.14% | +83.87% | +32.38% | 13.03B | |
| Average | +0.17% | -1.08% | +66.70% | +112.49% | 29.51B | |
| Weighted average by Cap. | -0.05% | -1.10% | +77.85% | +133.58% |
Employees
26
